Try our Advanced Search for more refined results

Expert Analysis

High Court Brings Economics Back To Pay-For-Delay Analysis

Law360, New York (June 17, 2013, 6:07 PM EDT) -- In its much-anticipated decision in Federal Trade Commission v. Actavis Inc. et al., the U.S. Supreme Court ruled 5-3 that the analysis of so-called "reverse payment" settlements of Paragraph IV abbreviated new drug application litigation in the pharmaceutical industry should be carried out under the rule of reason. In doing so, the court resolved a circuit split, rejecting both the "scope of the patent" approach and the FTC's proposed presumption of illegality, putting the question squarely back in the realm of economics, where it belongs....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!